Drug General Information
Drug ID
D0X1TN
Former ID
DIB020935
Drug Name
sergliflozin
Drug Type
Small molecular drug
Indication Discovery agent Investigative [467826]
Structure
Download
2D MOL
Formula
C23H28O9
InChI
InChI=1S/C23H28O9/c1-3-29-23(27)30-13-18-19(24)20(25)21(26)22(32-18)31-17-7-5-4-6-15(17)12-14-8-10-16(28-2)11-9-14/h4-11,18-22,24-26H,3,12-13H2,1-2H3/t18-,19-,20+,21-,22-/m1/s1
InChIKey
QLXKHBNJTPICNF-QMCAAQAGSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) SLGT2 Target Info Inhibitor [528482]
Sodium/glucose cotransporter 1 Target Info Inhibitor [528482]
KEGG Pathway Carbohydrate digestion and absorption
Bile secretion
Mineral absorption
PathWhiz Pathway Lactose Degradation
Trehalose Degradation
Reactome Hexose transport
Na+-dependent glucose transporters
Inositol transportersR-HSA-189200:Hexose transport
Inositol transporters
WikiPathways NRF2 pathway
Nuclear Receptors Meta-Pathway
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP2884:NRF2 pathway
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
Metabolism of carbohydrates
References
Ref 467826(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4587).
Ref 528482Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007 Jan;320(1):323-30. Epub 2006 Oct 18.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.